$ACHN Recent News Stocks trim Ukraine-inspired fall,

New Post Public Reply Private Reply Replies (0) Message Board

Aug 16, 2014 at 12:33 PM

$ACHN Recent News

Stocks trim Ukraine-inspired fall, post weekly gain 4:08 p.m. Aug. 15, 2014 - Anora Mahmudova
In focus: New highs premature? 9:03 p.m. June 18, 2014 - Lawrence G. McMillan
Achillion shares up; FDA lifts hold on hepatitis C drug 10:25 a.m. June 10, 2014 - Anna Prior
U.S. stock futures sink on shutdown fears 8:38 a.m. Sept. 30, 2013 - Barbara Kollmeyer
Zynga shares rise, Achillion drops after hours 5:51 p.m. July 1, 2013 - Wallace Witkowski
FDA puts Achillion Hep C drug on clinical hold 5:16 p.m. July 1, 2013 - MarketWatch.com
Five stocks making moves 3:12 p.m. Feb. 14, 2013 - The Trading Deck
Thursday’s top gaining & declining stocks 5:02 p.m. Sept. 27, 2012 - Greg Morcroft
Achillion sees progress in hepatitis C study 9:04 a.m. Sept. 27, 2012 - MarketWatch.com
Vertex to advance testing of oral HCV drug regimen 10:34 a.m. Sept. 25, 2012 - Val Brickates Kennedy
Wednesday’s biggest gaining and declining stocks 4:37 p.m. Sept. 19, 2012 - MarketWatch
Achillion, Idenix move on price target changes 10:29 a.m. Sept. 19, 2012 - Val Brickates Kennedy
Gilead boosted as analysts hike price targets 10:42 a.m. Sept. 17, 2012 - Val Brickates Kennedy
Thursday’s biggest gaining and declining stocks 4:47 p.m. Aug. 16, 2012 - MarketWatch
Idenix plunges 30% on HCV drug setback 12:56 p.m. Aug. 16, 2012 - Val Brickates Kennedy
Bristol’s bad news is good for rivals: analysts 5:52 p.m. Aug. 2, 2012 - Val Brickates Kennedy
Gilead shares boosted by Bristol-Myers drug news 11:24 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Bristol-Myers falls 7% on hepatitis C drug setback 10:09 a.m. Aug. 2, 2012 - Val Brickates Kennedy
Stocks to watch Thursday: Annie’s, Rite Aid 5:02 p.m. June 6, 2012 - David B. Wilkerson
Achillion's chief medical officer resigns 4:19 p.m. June 6, 2012 - Val Brickates Kennedy

10 Analyst Stocks to Buy Under $10 With Massive Upside Calls 9:47 a.m. Today - 247WallSt.com
Biotech Leader Gilead Sciences Scores Sovaldi Win 5:10 p.m. Aug. 15, 2014 - Investors Business Daily
Markets Close The Week On Negative Note As Ukraine Worries Mount 4:01 p.m. Aug. 15, 2014 - benzinga.com
U.S. Stocks Turn Lower; Dillard's Shares Slide On Downbeat Earnings 12:23 p.m. Aug. 15, 2014 - benzinga.com
Gilead Wins Sovaldi Dispute With Roche, U.K. Nod 11:23 a.m. Aug. 15, 2014 - Investors Business Daily
ACH-3102 + Sovaldi = 100% 11:03 a.m. Aug. 15, 2014 - Seeking Alpha
Markets Gain; J.C. Penney Posts Narrower-Than-Expected Q2 Loss 10:23 a.m. Aug. 15, 2014 - benzinga.com
Why Achillion Pharmaceuticals (ACHN) Stock Surged to a One-Year High Today 10:05 a.m. Aug. 15, 2014 - TheStreet.com
Stocks Hitting 52-Week Highs 9:24 a.m. Aug. 15, 2014 - benzinga.com
Morning Market Movers 8:40 a.m. Aug. 15, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Monster, Gilead, JCPenney, JDSU, Green Mountain and More 7:40 a.m. Aug. 15, 2014 - 247WallSt.com
Cramer's Mad Money - One Of The Highest Quality Companies In The World (8/14/14) 5:39 a.m. Aug. 15, 2014 - Seeking Alpha
Achillion Pharmaceuticals Up on Narrower-than-Expected Loss - Analyst Blog 9:10 a.m. Aug. 11, 2014 - Zacks.com
Benzinga's Top Upgrades 7:54 a.m. Aug. 11, 2014 - benzinga.com
Piper Jaffray Upgrades Achillion Pharmaceuticals To Overweight 7:19 a.m. Aug. 11, 2014 - benzinga.com
Benzinga's Top #PreMarket Gainers 7:05 a.m. Aug. 11, 2014 - benzinga.com
Top Analyst Upgrades and Downgrades: Achillion, Gap, GNC, King Digital, Pepsi, Tesla and More 7:00 a.m. Aug. 11, 2014 - 247WallSt.com
10-Q: ACHILLION PHARMACEUTICALS INC 4:04 p.m. Aug. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
Exclusive: Enanta Pharmaceuticals CEO Jay Luly Discusses Hep C Pipeline 8:39 a.m. July 3, 2014 - benzinga.com
Exclusive: Hepatitis C Stock Valuation With Enanta CEO Jay Luly 2:49 p.m. June 27, 2014 - benzinga.com

Achillion Achieves 100 Percent Sustained Virologic Response Rate (SVR4) From an Eight Week Phase 2 Trial Evaluating a Ribavirin-Free Regimen of ACH-3102 and Sofosbuvir for Genotype 1 HCV ("Proxy Study"

7:00 a.m. Aug. 15, 2014 - GlobeNewswire
Pre-Market Review on Biotech Equities -- Exelixis, Novavax, Achillion Pharma, XOMA, and Amicus Therapeutics 8:50 a.m. Aug. 13, 2014 - PR Newswire - PRF
Achillion Reports Second Quarter and Six Month 2014 Financial Results 4:06 p.m. Aug. 7, 2014 - GlobeNewswire
Critical Alerts For Achillion Pharmaceuticals, Synergy Resources, Invensense, JinkoSolar, and Harley-Davidson Released By InvestorsObserver 9:31 a.m. Aug. 5, 2014 - PR Newswire - PRF
Critical Alerts For Exelixis, Rocket Fuel, Netflix, Johnson & Johnson, and Achillion Pharmaceuticals Released By InvestorsObserver 9:31 a.m. July 15, 2014 - PR Newswire - PRF
Technical Data on Health Care Sector Equities -- Research on Achillion Pharma, Novavax, Dendreon, and Exelixis 7:00 a.m. July 10, 2014 - PR Newswire - PRF
Agreements, NDA Submissions, FDA Approvals, Enrollment Updates, and Index Inclusions - Analyst Notes on Jazz Pharmaceuticals, Vertex, NPS, StemCells and Achillion 5:50 a.m. July 7, 2014 - PR Newswire - PRF
Achillion Pharmaceuticals Added to the Russell 2000 and Russell Microcap Indexes 4:06 p.m. July 1, 2014 - GlobeNewswire
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver 9:31 a.m. June 17, 2014 - PR Newswire - PRF
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc. 7:00 a.m. June 13, 2014 - PR Newswire - PRF
Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos 5:20 a.m. June 12, 2014 - PR Newswire - PRF
Achillion to Present at Two Upcoming Investor Conferences 6:06 a.m. June 11, 2014 - GlobeNewswire
Achillion Announces Initiation of ACH-3422 Dosing in HCV-Infected Patients and Ability to Resume Sovaprevir Clinical Program for the Treatment of Chronic HCV 6:06 a.m. June 10, 2014 - GlobeNewswire
Biotech Equities under the Scanner -- Research on Halozyme Therapeutics, Medivation, Achillion Pharma, and Alexion Pharma 8:10 a.m. June 6, 2014 - PR Newswire - PRF
Biotech Equities Under Review -- Research on Achillion Pharma, Mast Therapeutics, Alkermes, and Momenta Pharma 1:30 p.m. May 9, 2014 - PR Newswire - PRF
Achillion Reports First Quarter 2014 Financial Results 6:06 a.m. May 7, 2014 - GlobeNewswire
Achillion to Present at Three Upcoming Investor Conferences 6:31 a.m. May 1, 2014 - GlobeNewswire
Achillion Advances ACH-3422, Uridine-Analog Nucleotide Inhibitor, Into Clinical Trial; Initiates Phase 2 Pilot Study With ACH-3102, NS5A Inhibitor, for HCV 4:07 p.m. April 30, 2014 - GlobeNewswire
Biotech Stocks Review -- Research on Achillion Pharma, Medivation, Mast Therapeutics, and Athersys 8:16 a.m. April 14, 2014 - PR Newswire - PRF
Morning Analysis on Top Gainers -- Research on Achillion Pharma, Microvision, Miller Energy Resources, and Bon-Ton Stores 11:24 a.m. March 25, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Bank Leumi Q3 Earnings Preview: Key Dates & Insights

A Closer Look at Bank Leumi's Upcoming Q3 Release Take a seat, folks. Bank Leumi’s gearing up to spill the beans on their Third Quarter 2026 earnings come November 17th. If you’re in the financial world, you might want to mark your calendar because these reports tend to shake things up. You know how these go - numbers rolling out, market responses, and plenty of...

Domino’s Faces Legal Heat: Investors' Eyes On DPZ

Domino's Pizza Under the Legal Microscope Picture this, folks: Domino's Pizza (NASDAQ: DPZ) is caught in a legal whirlwind that might give its shareholders a rollercoaster of a read in the coming weeks. On the docket is a serious probe led by Johnson Fistel, a law outfit with quite the reputation for defending shareholder interests. The focus? Whether certain hot shots at...

xTool X1: Redefining Laser Fabrication for Makers

The Next Generation of Laser Fabrication Whenever a new gizmo hits the market, it's usually just an upgrade in disguise—faster, shinier, a touch more wattage. Not this time. xTool shook things up by rolling out the X1, a laser platform that gets what small businesses and makers truly crave: versatility and long-lasting potential. This bad boy does more than engrave; it...

BD's New Liverty™ TIPS Stent: A Game Changer?

Could This Be the Breakthrough for Portal Hypertension? Now, here's something that might just turn a few heads in the medical world. BD has launched their Liverty™ TIPS Stent Graft in the U.S., a move set to shake up the landscape for treating portal hypertension. This isn't just another shiny new gadget—it's a promise of more personalized patient care in a field...

BASIS Bellevue Expands with New K-4 Campus

A New Era for Young Learners in Bellevue When a community-driven school like BASIS Independent Bellevue makes a move to expand, it doesn't happen in a vacuum. They're not just building another campus—they're aiming to sculpt the future right here in Bellevue, and boy, do they have a plan. The new Lower School campus opening come Fall 2027 is dedicated to kiddos in...

EzAccounting: Your Q3 IRS Filing Gets a No-Nonsense Tool

Taking Tax Deadlines Head-On Tax season's got businesses sweating all over the country, but it doesn't have to be a full-scale panic attack if you've got the right gear. That's where ezAccounting steps in, dishing out a reliable solution to hit those looming IRS Form 941 deadlines without a migraine. By November 2, 2026, companies are looking to dodge the bullet of...

Amgen Q3 2026 Results: What Investors Should Know

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

California Cash Surplus Raises Investor Eyebrows

California's Unexpected Financial Bounty Kicking things off with a real humdinger: California's September cash flow exceeded expectations by a whopping $2.9 billion. That's not chump change, folks. It's like finding an extra twenty in your coat pocket but on a much grander scale. Impressively, the state's General Fund receipts tallied up to $22.9 billion, surpassing the...

York Space Systems Faces Turbulence Amid Investor Lawsuit

York's Shaky Strategy Under the Microscope How do you go from sky-high ambitions to a grinding halt in a matter of weeks? This ain’t your typical Wall Street plot twist—it involves York Space Systems, or NYSE:YSS. These guys promised dominance in the Space Development Agency’s Transport Layer program, only to have their shooting star come crashing down. And now,...

Review Insurance Coverage After Major Life Changes

Why Life Changes Demand an Insurance Review The nitty-gritty of life doesn't sit still—marriages, babies, job changes, and home deals or steals each bring their own clutter to the table. One thing's for sure: when your life shifts, your insurance ought to keep pace. Insurance Agent Nick Hogan drops the dime in the latest HelloNation article, laying it bare why...